Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Raymond James analyst Steven Seedhouse downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Outperform to Market Perform.
NGM Biopharmaceuticals (NASDAQ:NGM) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of...
TD Cowen analyst Ritu Baral downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Outperform to Market Perform and lowers the ...
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter...
Explore NGM Bio's acquisition news by The Column Group at $1.55/share, an 80% premium. Learn about the recent Phase 1b stud...
